The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...

Bendamustine is generally well tolerated. The most common serious (grade 3 or 4) adverse events are hematologic in nature. Gastrointestinal events are also commonly observed but are usually mild ...

FDA grants traditional approval for Calquence with bendamustine and Rituxan for untreated MCL patients ... second primary malignancy, rash, febrile neutropenia, atrial fibrillation, sepsis and anemia.